- Conditions
- Migraine
- Interventions
- duloxetine
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 84
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Episodic Migraine
- Interventions
- Atogepant 60 mg, Placebo
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 315 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 26
- States / cities
- Colton, California • Encino, California • Los Alamitos, California + 20 more
- Conditions
- Episodic Migraine
- Interventions
- DFN-11, Placebo
- Drug · Other
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 268 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 16
- States / cities
- Santa Monica, California • Jacksonville, Florida • Maitland, Florida + 13 more
- Conditions
- Migraine With or Without Aura
- Interventions
- Low-Dose Naltrexone and Acetaminophen Combination, Placebo
- Drug
- Lead sponsor
- Allodynic Therapeutics, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- North Miami, Florida
- Conditions
- Migraine
- Interventions
- Erenumab
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 240 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 42
- States / cities
- Huntsville, Alabama • Phoenix, Arizona • Fullerton, California + 38 more
- Conditions
- Migraine, Migraine Headache, Episodic Migraine Headache
- Interventions
- Cognitive behavioral therapy for migraine (CBTm), MEintervention
- Behavioral
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 2
- States / cities
- West Haven, Connecticut • San Antonio, Texas
- Conditions
- Migraine
- Interventions
- EVO756, Dose 1, EVO756, Dose 2, Placebo
- Drug
- Lead sponsor
- Evommune, Inc.
- Industry
- Eligibility
- 18 Years to 64 Years
- Enrollment
- 330 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 26
- States / cities
- Chandler, Arizona • Buena Park, California • Fresno, California + 21 more
- Conditions
- Migraine
- Interventions
- Olanzapine during first intervention period and placebo during second intervention period, Placebo during first intervention period, then olanzapine during second intervention period
- Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2006
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Migraine
- Interventions
- Erenumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 512 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 31
- States / cities
- Long Beach, California • Los Angeles, California • Basalt, Colorado + 28 more
- Conditions
- Episodic Migraine
- Interventions
- saline placebo, Ibuprofen
- Other · Drug
- Lead sponsor
- Thomas Jefferson University
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2017
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Migraine
- Interventions
- Erenumab Dose 1, Erenumab Dose 2, Erenumab Dose 3, Placebo
- Drug · Other
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 6 Years to 17 Years
- Enrollment
- 457 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 38
- States / cities
- San Diego, California • Aurora, Colorado • Colorado Springs, Colorado + 32 more
- Conditions
- Headache
- Interventions
- Not listed
- Lead sponsor
- Montefiore Medical Center
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 477 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2005
- U.S. locations
- 1
- States / cities
- The Bronx, New York
- Conditions
- Migraine, Episodic Migraine, Headache, Headache, Migraine
- Interventions
- ReMMi-D Digital Therapeutic
- Device
- Lead sponsor
- Click Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 568 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Migraine
- Interventions
- Active Comparator, Sham Comparator
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 44 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Episodic Migraine
- Interventions
- Atogepant, Ubrogepant
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 263 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 37
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • Oceanside, California + 34 more
- Conditions
- Episodic Migraine
- Interventions
- Atogepant
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 685 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 113
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Tucson, Arizona + 91 more
- Conditions
- Migraine Headaches
- Interventions
- Sumatriptan 10 mg Nasal Spray, Sumatriptan Placebo Nasal Spray
- Drug · Other
- Lead sponsor
- Upsher-Smith Laboratories
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 107 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 9
- States / cities
- San Diego, California • Santa Monica, California • Boston, Massachusetts + 6 more
- Conditions
- Migraine
- Interventions
- Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing, Placebo comparator dosing
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,415 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 30
- States / cities
- Tempe, Arizona • Colton, California • Los Angeles, California + 27 more
- Conditions
- Episodic Migraine Headache
- Interventions
- LBR-101 High Dose, LBR-101 Low Dose, Placebo
- Drug
- Lead sponsor
- Teva Branded Pharmaceutical Products R&D, Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 297 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 63
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 56 more
- Conditions
- Migraine, Episodic Migraine
- Interventions
- Galcanezumab, Rimegepant, Placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 580 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 77
- States / cities
- Gilbert, Arizona • Phoenix, Arizona • Tempe, Arizona + 71 more
- Conditions
- Episodic Migraine
- Interventions
- Xeomin, Placebo
- Drug
- Lead sponsor
- Merz Therapeutics GmbH
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 990 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 47
- States / cities
- Chandler, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 43 more
- Conditions
- Episodic Migraine
- Interventions
- AMG334, Oral Prophylactic
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 621 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 20
- States / cities
- Stanford, California • New Haven, Connecticut • Stamford, Connecticut + 17 more
- Conditions
- Episodic Migraine
- Interventions
- Chiropractic Care, Headache Health Education
- Procedure · Behavioral
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Migraine
- Interventions
- Lu AG09222, Placebo
- Drug
- Lead sponsor
- H. Lundbeck A/S
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 874 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2026
- U.S. locations
- 28
- States / cities
- Hoover, Alabama • Carlsbad, California • Fullerton, California + 24 more